Epidermal growth factor receptor T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study. | |
Zhang, SR; Zhu, LC; Xia, B; Chen, EG; Zhao, Q; Zhang, XC; Chen, XQ; Chen, XF; Ma, SL | |
刊名 | CANCER COMMUNICATIONS
![]() |
2018 | |
卷号 | Vol.38 |
关键词 | Epidermal growth factor receptor Failure sites Non-small cell lung cancer T790M ctDNA |
ISSN号 | 2523-3548;2523-3548 |
URL标识 | 查看原文 |
公开日期 | [db:dc_date_available] |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/5462158 |
专题 | 湖南大学 |
作者单位 | 1.Nanjing Med Univ, Hangzhou Peoples Hosp 1, Ctr Translat Med, 261 Huansha Rd, Hangzhou 310006, Zhejiang, Peoples R China 2.Nanjing Med Univ, Hangzhou Peoples Hosp 1, Dept Oncol, Hangzhou 310006, Zhejiang, Peoples R China 3.Hangzhou Canc Hosp, Dept Oncol, Hangzhou 310000, Zhejiang, Peoples R China 4.Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Resp, Hangzhou 310020, Zhejiang, Peoples R China 5.Zhejiang Univ, Affiliated Hosp 1, Dept Oncol, Hangzhou 310006, Zhejiang, Peoples R China 6.City Hope Natl Med Ctr, Dept Canc Genet & Epigenet, Duarte, CA 91010 USA |
推荐引用方式 GB/T 7714 | Zhang, SR,Zhu, LC,Xia, B,et al. Epidermal growth factor receptor T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.[J]. CANCER COMMUNICATIONS,2018,Vol.38. |
APA | Zhang, SR.,Zhu, LC.,Xia, B.,Chen, EG.,Zhao, Q.,...&Ma, SL.(2018).Epidermal growth factor receptor T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study..CANCER COMMUNICATIONS,Vol.38. |
MLA | Zhang, SR,et al."Epidermal growth factor receptor T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.".CANCER COMMUNICATIONS Vol.38(2018). |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论